Raju Prasad
Stock Analyst at William Blair
(n/a)
# 4,357
Out of 4,667 analysts
12
Total ratings
n/a
Success rate
-42.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Raju Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DTIL Precision BioSciences | Downgrades: Market Perform | n/a | $6.43 | - | 1 | Jun 9, 2022 | |
| NTLA Intellia Therapeutics | Initiates: Outperform | n/a | $14.02 | - | 1 | Feb 18, 2022 | |
| LOGC ContextLogic | Downgrades: Market Perform | n/a | $6.85 | - | 1 | Feb 3, 2022 | |
| ASMB Assembly Biosciences | Downgrades: Market Perform | n/a | $14.87 | - | 1 | Sep 2, 2021 | |
| VERV Verve Therapeutics | Initiates: Outperform | $92 | $4.64 | +1,882.76% | 1 | Jul 12, 2021 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $46 | $2.18 | +2,010.09% | 1 | Feb 24, 2021 | |
| GBIO Generation Bio Co. | Initiates: Outperform | $45 | $1.34 | +3,258.21% | 1 | Feb 24, 2021 | |
| CRSP CRISPR Therapeutics AG | Initiates: Market Perform | n/a | $46.01 | - | 1 | Mar 14, 2019 | |
| BOLD Boundless Bio | Downgrades: Market Perform | n/a | $2.61 | - | 2 | Nov 7, 2018 | |
| PTCT PTC Therapeutics | Upgrades: Outperform | n/a | $43.30 | - | 2 | Jun 18, 2018 |
Precision BioSciences
Jun 9, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.43
Upside: -
Intellia Therapeutics
Feb 18, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.02
Upside: -
ContextLogic
Feb 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.85
Upside: -
Assembly Biosciences
Sep 2, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $14.87
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Outperform
Price Target: $92
Current: $4.64
Upside: +1,882.76%
Taysha Gene Therapies
Feb 24, 2021
Initiates: Outperform
Price Target: $46
Current: $2.18
Upside: +2,010.09%
Generation Bio Co.
Feb 24, 2021
Initiates: Outperform
Price Target: $45
Current: $1.34
Upside: +3,258.21%
CRISPR Therapeutics AG
Mar 14, 2019
Initiates: Market Perform
Price Target: n/a
Current: $46.01
Upside: -
Boundless Bio
Nov 7, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $2.61
Upside: -
PTC Therapeutics
Jun 18, 2018
Upgrades: Outperform
Price Target: n/a
Current: $43.30
Upside: -